Literature DB >> 22859923

Biologicals and bone loss.

Charlotte L M Krieckaert1, Willem F Lems.   

Abstract

Inflammatory joint diseases are associated with extra-articular side effects including bone involvement.There is an increased risk of osteoporotic fractures. The pathogeneses of local and generalized bone loss share a common pathway. Early and active rheumatoid arthritis is associated with longitudinal observed bone loss and fracture rate is of vertebral and nonvertebral fractures is doubled compared with matched healthy controls. Lowering disease activity with TNF inhibitors or is associated with stabilisation of bone mineral density by counteracting elevated bone resorption.

Entities:  

Keywords:  ankylosing spondylitis biologicals; bone mineral density; fracture risk; osteoporosis; rheumatoid arthritis

Year:  2012        PMID: 22859923      PMCID: PMC3403251          DOI: 10.1177/1759720X12441275

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  16 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  How antirheumatic drugs protect joints from damage in rheumatoid arthritis.

Authors:  Georg Schett; Christian Stach; Jochen Zwerina; Reinhard Voll; Bernhard Manger
Journal:  Arthritis Rheum       Date:  2008-10

3.  The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.

Authors:  Kwi Young Kang; Kwan Yong Lee; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Soo Park; Yeon Sik Hong; Ho-Youn Kim; Sung-Hwan Park
Journal:  Joint Bone Spine       Date:  2011-03       Impact factor: 4.929

4.  Generalised bone loss in patients with early rheumatoid arthritis.

Authors:  A K Gough; J Lilley; S Eyre; R L Holder; P Emery
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321

5.  Factors influencing bone loss in rheumatoid arthritis: a longitudinal study.

Authors:  B Cortet; M H Guyot; E Solau; P Pigny; F Dumoulin; R M Flipo; X Marchandise; B Delcambre
Journal:  Clin Exp Rheumatol       Date:  2000 Nov-Dec       Impact factor: 4.473

6.  Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis.

Authors:  G Wheater; V E Hogan; Y K O Teng; J Tekstra; F P Lafeber; T W J Huizinga; J W J Bijlsma; R M Francis; S P Tuck; H K Datta; J M van Laar
Journal:  Osteoporos Int       Date:  2011-04-06       Impact factor: 4.507

7.  Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register.

Authors:  G Haugeberg; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Arthritis Rheum       Date:  2000-12

8.  Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register.

Authors:  G Haugeberg; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Arthritis Rheum       Date:  2000-03

Review 9.  Bone remodeling in rheumatic disease: a question of balance.

Authors:  Nicole C Walsh; Ellen M Gravallese
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

10.  Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.

Authors:  C A Wijbrandts; R Klaasen; M G W Dijkgraaf; D M Gerlag; B L F van Eck-Smit; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-04-13       Impact factor: 19.103

View more
  2 in total

1.  Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study.

Authors:  L Oei; N Campos-Obando; A Dehghan; E H G Oei; L Stolk; J B J van Meurs; A Hofman; A G Uitterlinden; O H Franco; M C Zillikens; F Rivadeneira
Journal:  Osteoporos Int       Date:  2013-12-13       Impact factor: 4.507

Review 2.  C-reactive protein and risk of fracture: a systematic review and dose-response meta-analysis of prospective cohort studies.

Authors:  Z-J Wu; J-L He; R-Q Wei; B Liu; X Lin; J Guan; Y-B Lan
Journal:  Osteoporos Int       Date:  2014-08-09       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.